The global Belimumab industry is projected to experience robust expansion, driven by the increasing prevalence of autoimmune disorders, particularly Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN). Market analyses indicate a dynamic growth trajectory, reinforcing Belimumab’s position as a cornerstone therapy in immunology. https://www.databridgemarketresearch.com/reports/global-belimumab-market